Most colorectal patients report financial burden due to treatment
the ONA take:
The burden of cancer and its treatment goes beyond the obvious medical and physical challenges. Many patients experience significant financial hardship as well. Researchers at the University of Michigan Comprehensive Cancer Center conducted a study on the financial burden of colorectal cancer.
They surveyed 956 patients identified through the Surveillance, Epidemiology and End Results cancer registries for the Metro Detroit area and the stage of Georgia. The patients were asked to complete a seven-question survey that asked whether they employed such financial strategies as using savings, borrowing money, skipping bill payments, or cutting back on expenses (eg, food, clothing, or recreational activities).
Overall, 62% of respondents indicated areas of burdens, based on the seven questions. More specifically, the study demonstrated that younger patients who worked in low-paying jobs and those who received chemotherapy were most likely to endure financial burdens.
Based on their findings, the researchers advocate changes to job-related policies that would allow patients to focus on adhering to their treatments, and provide support for both copays and nonmedical expenses related to getting to treatment appointments. Most importantly, however, the researchers encourage clinicians to openly discuss financial situations and support options with patients.
Researchers conducted a study on the financial burden of colorectal cancer.
Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The burden was greatest among patients who received chemotherapy and among younger patients who worked in low-paying jobs.
The study surveyed 956 patients who had been treated for stage 3 colorectal cancer. Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following surgery.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|